Stockscreener 앱 받기
0.6952
3.44%
-0.0248
시장 영업 전:
.70
0.0048
+0.69%
전일 마감가:
$0.72
열려 있는:
$0.7235
하루 거래량:
256.70K
Relative Volume:
0.03
시가총액:
$5.91M
수익:
-
순이익/손실:
$-22.71M
주가수익비율:
-0.0594
EPS:
-11.71
순현금흐름:
$-18.24M
1주 성능:
-5.80%
1개월 성능:
-23.60%
6개월 성능:
-64.16%
1년 성능:
-91.68%
1일 변동 폭
$0.6555
$0.7339
1주일 범위
$0.6555
$0.7496
52주 변동 폭
$0.2806
$335.84
Genprex Inc Stock (GNPX) Company Profile
명칭
Genprex Inc
전화
512-537-7997
주소
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
GNPX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.6952 | 5.91M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-01-26 | 개시 | National Securities | Buy |
| 2019-04-29 | 개시 | Noble Capital Markets | Outperform |
Genprex Inc 주식(GNPX)의 최신 뉴스
Genprex, Inc. (NASDAQ: GNPX) Provides Updates on Oncology and Diabetes Programs - Defense World
Genprex Advances Cancer Trials and Diabetes Therapy - Yahoo Finance
Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
SEC Form 424B5 filed by Genprex Inc. - Quantisnow
Genprex Completes Phase 1 Dose Escalation of Acclaim-3 Clinical Trial for ES-SCLC PatientsGenprex, Inc. (NASDAQ:GNPX) announced in a press release dated December 16, 2024, the successful completion of the Phase 1 dose escalation segment of the - Defense World
Genprex advances to phase 2 in lung cancer trial - Investing.com
Genprex's Reqorsa Advances to Phase 2 After Successful Safety Trial in Lung Cancer Treatment - StockTitan
Genprex to Present and Participate at Upcoming September Investor and Industry Conferences - The Eastern Progress Online
Genprex to Participate in 2024 BIO Europe Conference - The Eastern Progress Online
Genprex Collaborators Present Positive Preclinical Data on the U - GuruFocus.com
Genprex Collaborators to Present Positive Preclinical Data on th - GuruFocus.com
Genprex links with University of Michigan on lung cancer treatment - Yahoo Finance
Genprex secures exclusive gene therapy license for cancer By Investing.com - Investing.com Canada
Genprex secures exclusive gene therapy license for cancer - Investing.com India
Genprex Secures Global Patent Rights for Breakthrough Lung Cancer Gene Therapy | GNPX Stock News - StockTitan
Genprex faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia
Genprex faces Nasdaq delisting over equity shortfall - Investing.com India
U.S. Stock market top gainers: Mullen Automotive gains 92.92% while Genprex increases by 54.48% during mid day trading - Business Upturn
'Animal spirits' set to drive S&P 500 to 6,600 by mid-2025, Evercore says - Investing.com
Genprex reports promising preclinical data on cancer therapy - Investing.com
Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting - BioSpace
Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Thera - GuruFocus.com
Genprex regains Nasdaq compliance with bid price rule - Investing.com India
Genprex regains Nasdaq compliance with bid price rule By Investing.com - Investing.com Australia
Genprex reports promising preclinical data on cancer therapy By Investing.com - Investing.com UK
Genprex Announces Sponsored Research Agreement with The Universi - GuruFocus.com
Short Interest in Genprex, Inc. (NASDAQ:GNPX) Increases By 5.2% - Defense World
Investor Excitement Sparks Genprex (GNPX) Stock Rally - Stocks Telegraph
Genprex reports positive preclinical gene therapy data By Investing.com - Investing.com South Africa
Genprex reports positive preclinical gene therapy data - Investing.com India
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma - The Malaysian Reserve
Genprex (NASDAQ:GNPX) Announces Sponsored Research Agreement with University of Michigan Rogel Cancer Center for Study on TUSC2 Gene Therapy in ALK-Positive Lung Cancer Patients - Defense World
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.80% - MSN
Genprex explores gene therapy in lung cancer study - Investing.com India
Genprex explores gene therapy in lung cancer study By Investing.com - Investing.com South Africa
Genprex signs two lung cancer research agreements - TipRanks
Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive - StreetInsider.com
3 Penny Stocks to Watch Now, 10/24/24 - TipRanks
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.02% - MSN
2 No-Brainer Artificial Intelligence (AI) Stocks to Buy Right Now - Yahoo Finance
Dow Falls Over 150 Points; General Motors Tops Q3 Views - Benzinga
‘Permanent should mean Permanent’: Purbeck calls for commitment to Full Expensing - Yahoo! Voices
TD Bank becomes liquidity provider for LTX - Yahoo! Voices
UK economy 'set to accelerate', says IMF - Yahoo! Voices
Genprex Inc (GNPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.81%
자본화:
|
볼륨(24시간):